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to plaques (Simard et al., 2006). However, there is rea-
son to be cautious about overexpression of CatB, which
has been reported to contribute to neurotoxic effects of
microglia (Gan et al., 2004; Kingham and Pocock, 2001).
Of course, there may be other ways to increase intracel-
lular CatB expression with small molecules. Whether or
not the new findings lead to CatB-based therapeutics,
the evidence for this normal clearance tale for Ab aggre-
gates is clearly an important new chapter for the AD re-
search field. And with any luck, this will not end as just
a Cat in mouse story.
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Figure 1. Schematic Diagram Showing the Role of Cathepsin B in
Amyloid Clearance
Mueller-Steiner et al. demonstrate that cathepsin B (CatB) can clear
fibrillar amyloid-b. CatB can be secreted (arrows) into plaques
(green star) and promote the degradation of extracellular amyloid-
b. A major potential source of CatB in plaques may be microglia (or-
ange), which secrete avidly in vitro, but other cell types (astrocytes,
blue top left) and neurons (gray, right) may also contribute CatB to
plaques. The green circles with ‘‘B’’ represent endosomes or lyso-
somes containing CatB, where it may degrade intracellular Ab. It is
unclear whether CatB secreted from neurons is primarily dendritic





Mutations in GARS cause dominantly inherited neu-
ropathies in humans.GARS encodes glycyl-tRNA syn-
thetase, the enzyme that couples glycine to its tRNA. In
this issue of Neuron, Seburn et al. have identified and
characterized a mutant mouse with a dominantly in-
herited axonal neuropathy caused by a Gars mutation
that is inferred to have a gain of function.
In 1886, Charcot, Marie, and Tooth described patients
who are now understood as having a dominantly in-
herited neuropathy that affects myelinated motor and
sensory axons in a length-dependent manner. This dis-
order is usually called Charcot-Marie-Tooth disease, or
simply CMT, and is one of the most common inherited
neurological diseases (Lupski and Garcia, 2001; Shy
et al., 2005; Wrabetz et al., 2004). Like most kinds of neu-
ropathy, CMT is characterized by progressive dysfunc-
tion that is related to the length of the affected axons.
The longest sensory and motor axons are affected first
and are more affected over time. This progressive,
length-dependent dying back of motor and sensory
axons produces the classic clinical picture of distally
accentuated weakness, atrophy, and sensory loss.
By 1980, a few different kinds of CMT were clinically
recognized. The demyelinating form was termed CMT1
and is characterized by slowed nerve conduction veloc-
ities and evidence of demyelination and remyelination in
nerve biopsies. The neuronal/axonal form was termed
CMT2, characterized by relatively normal conduction
velocities and axonal loss but not demyelination/remye-
lination in nerve biopsies. The more severe kinds of de-
myelinating neuropathy that start in infancy or childhood
retained different names (congenital hypomyelinating
neuropathy or Dejerine-Sottas neuropathy, respec-
tively), and their relationship to CMT was not under-
stood. The terms hereditary motor neuropathies and
Previews
673distal spinal muscular atrophy (even the names under-
score the uncertainty of whether motor neurons or just
their axons are the locus of disease) were used for cases
in which motor but not sensory axons are affected in
a length-dependent manner. Similarly, the term heredi-
tary sensory neuropathy was given to a group of disor-
ders in which the sensory neurons/axons are dispropor-
tionately more affected than are motor neurons/axons.
The molecular basis of these disorders has been in-
creasing illuminated over the last 25 years. Each disor-
der shows remarkable genetic heterogeneity (www.
molgen.ua.ac.be/CMTMutations)—CMT1 (mutations in
five different genes), CMT2 (including three kinds of
so-called dominant intermediate CMT; 14 different
genes), hereditary sensory neuropathy (six), hereditary
motor neuropathy (eight), Dejerine-Sottas neuropathy
and congenital hypomyelinating neuropathy (five), and
recessive demyelinating (nine) and axonal (four) neurop-
athies. Further, different mutations in the same gene
produce different phenotypes. For example, dominant
mutations inMPZ, the gene that encodes P0, a structural
protein of the myelin sheath, produce several distinct
phenotypes, usually CMT1, but also CMT2, Dejerine-
Sottas neuropathy, and congenital hypomyelinating
neuropathy.
This explosion of knowledge is challenging to master
but presents opportunities to clinicians and scientists
alike. Informed clinicians can provide the precise molec-
ular diagnosis to patients, and the nature of the genetic
defect may suggest novel treatments. For example, du-
plication of thePMP22 gene (the most common cause of
CMT1) probably causes demyelination because three
(instead of two) copies of the gene result in modest over-
expression of peripheral myelin protein 22 kDa, thereby
destabilizing the myelin sheath. Thus, effective therapy
might be achieved by modestly decreasing the expres-
sion of PMP22 in a variety of ways (Passage et al.,
2004; Sereda et al., 2003). For scientists, the genes
that cause hereditary neuropathies provide unique in-
sights about which molecules are essential for the
proper functioning of myelinated axons. The molecular
defects that lead to neuropathy are not limited to those
that cause CMT or one of its variants, however, as there
are dozens of inherited diseases, including many kinds
of hereditary ataxia and spastic paraparesis, in which
neuropathy is part of the syndrome.
Because interactions between two different cell
types—myelinating Schwann cells and neurons—gener-
ate myelinated axons, it could have been anticipated
that there are two kinds of CMT. Demyelinating forms
arise from abnormalities that are intrinsic to myelinating
Schwann cells themselves, and axonal forms are the re-
sult of genetic defects that primarily affect neurons and
especially their axons. Given their known roles in myeli-
nating Schwann cells and axons, some genes could
have been predicted to cause neuropathy because
they encode components that are specifically ex-
pressed by myelinating Schwann cells (e.g., P0,
PMP22, periaxin) or neurons (e.g., neurofilament light
subunit). Many of the genes that cause CMT, however,
are expressed in multiple cells types (e.g., Connexin32,
NDRG1) or even ubiquitously (e.g., Mitofusin2, RAB7,
GARS). Why mutations in these widely expressed genes
result in peripheral neuropathy alone and not a morepervasive disorder remains mysterious. The case of
GARS is particularly perplexing, as glycine tRNA is re-
quired by all cells, and GARS is the only gene that is
known to possess glycyl-tRNA synthetase activity.
In this issue of Neuron, Seburn et al. (Seburn et al.,
2006) report their studies of Nmf249 mice, which were
identified at the Jackson Laboratory owing to their dom-
inantly inherited phenotype of progressive neuromuscu-
lar dysfunction that begins by 3 weeks of age. These
workers mapped the gene to a 1.9 mb region on chromo-
some 6 that contains the murine ortholog of GARS. Se-
quencing the Gars gene revealed a mutation that is pre-
dicted to replace Pro with LysTyr at 278. Although this
Pro residue is phylogenically conserved, this mutation
does not affect the activity of glycyl-tRNA synthetase
in a biochemical assay.
Seburn et al. (2006) thoroughly document an age-re-
lated decrease in the number of large myelinated motor
and sensory axons in GarsNmf249/+ mice. The loss of my-
elinated axons is length dependent, as myelinated mo-
tor axons are lost in distal nerves but not in the ventral
roots, and there is a length- and time-dependent de-
crease in motor innervation of distal versus proximal
muscles. The findings that most of the axonal loss oc-
curs by 1 month of age and that mice that survive this
period can be long lived have an uncanny similarity to
clinical descriptions of some kinds of CMT. These
pathological alterations are presumed to be the basis
for physiological abnormalities in the GarsNmf249/+
mice—reduced amplitudes of muscle compound action
potentials and a surprisingly large reduction in sciatic
nerve conduction velocity in the absence of demyelin-
ation or remyelination. These results demonstrate that
GarsNmf249/+ mice are a genetically authentic animal
model of CMT caused by dominant GARS mutations.
The availability of mice with anotherGars allele (XM256)
that is predicted to cause loss of function enabled Seburn
et al. (2006) to evaluate further the effects of the NMF249
allele. Unlike GarsNmf249/+ mice, GarsXM256/+ mice do not
develop neuropathy, further evidence that the dominant
effect of the NMF249 allele is not the result of haplotype
insufficiency. LikeGarsNmf249/Nmf249 andGarsXM256/XM256
mice, GarsNmf249/XM256 mice are embryonic lethal; the
failure of a null allele (XM256) to complement a dominant
allele (NMF249) indicates that the wild-type protein com-
pensates or competes with the mutant protein in a path-
ogenic gain of function. Variability of this dominant effect
may be the biological basis for why some GARS muta-
tions do not appear to affect myelinated sensory axons
and hence cause a motor neuropathy.
These results support the hypothesis that the pheno-
type of GarsNmf249/+ mice is caused by a novel patho-
genic function of the mutant glycyl-tRNA synthetase.
The mechanism is unknown, and possibilities include
noncanonical functions of glycyl-tRNA synthetase, as
these have been documented for other tRNA synthe-
tases. One presumes that the molecular mechanisms
of human and mouse glycyl-tRNA synthetase mutants
may relate to how dominant mutations in YARS (which
encodes tyrosyl-tRNA synthetase) cause a different
kind of CMT (Jordanova et al., 2006).
As the authors point out, there are interesting similar-
ities between the GarsNmf249/+ model of CMT4D and
mouse models of amyotrophic lateral sclerosis (ALS)
molecular mechanisms that determine how a neuron
specifies an axon and dendrites remain poorly under-
stood, it has become clear that the establishment and
maintenance of neuronal polarity depends upon the mi-
crotubule network. Many signaling cascades influence
microtubule dynamics in the developing axon. Targets
of these signaling pathways include microtubule motor
proteins (Wiggin et al., 2005) as well as structural micro-
tubule-associated proteins (MAPs) (Dehmelt and Hal-
pain, 2004). When the function of these molecules is per-
turbed, neuronal polarity is disrupted. This type of
disruption often results in neurons with multiple axons,
multiple dendrites, or many long neurites that lack axo-
nal or dendritic characteristics (Arimura and Kaibuchi,
2005; Wiggin et al., 2005). The signaling pathways up-
stream of the MAPs, however, are not well delineated.
In this issue of Neuron, studies from the Van Aelst
(Watabe-Uchida et al., 2006) group provide new insights
into a signaling pathway upstream of a specific MAP that
is mediated by a novel Rac-activating protein, DOCK7.
In other cell types, Rac has been shown to influence
the microtubule cytoskeleton (Wittmann et al., 2004).
However, little is known about its effect on microtubule
dynamics in neurons. Rac has been implicated in the
regulation of neuronal polarity. Perturbation of Rac pref-
erentially affects the outgrowth of axons but not den-
drites in vivo (Luo et al., 1996). The Par-6/Par-3/aPKC
polarity complex, which functions in axon specification,
may directly influence Rac activation by regulating Rac-
GEFs (guanine nucleotide exchange factors) (Nishimura
et al., 2005). It is not known whether these Rac-associ-
ated signaling pathways eventually influence the micro-
tubule cytoskeleton, and if so, through which MAPs.
The report by Watabe-Uchida et al. identifies a novel
Rac GTPase activator, DOCK7, that plays a crucial role
in axon formation. A member of the DOCK180-related
superfamily, DOCK7 is an unconventional GEF, directly
associating with Rac through its DHR2 domain. Al-
though DOCK180-related family members have been
shown to be regulators of polarization in different cell
types (Meller et al., 2005), DOCK7 is the first member
found to play a critical role in the early stages of axon
formation in hippocampal neurons. Watabe-Uchida
et al. observe that DOCK7 is concentrated in a single
neurite after immature neurites have formed. DOCK7 is
then selectively localized to the axon that forms. This
observation suggests that DOCK7 is involved in the ini-
tial specification of the axon. Overexpression of DOCK7
disrupts polarity by promoting multiple axon formation;
Neuron
674caused by dominant SOD1 mutations. Like GarsNmf249/+
mice, mice expressing dominant human SOD1 mutants
develop a length-dependent motor neuropathy that
was not anticipated from clinical investigations. Be-
cause of the difficulties in distinguishing neuropathies
from neuronopathies in humans, careful evaluation of
animal models may reveal that axonal degeneration is
the primary defect in a number of neurodegenerative
diseases. Although many of these diseases are defined
clinically owing to the particular populations of affected
neurons, axonal disease may be a final common path-
way that links them (Roy et al., 2005). A steady supply
of new genetic causes of neuropathy and informative
animal models will facilitate our understanding of the
causes and treatments of neuropathy, both inherited
and acquired, and perhaps even more complex dis-
orders.
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of Axon Formation
Microtubules play an important role in neuronal polar-
ity. In this issue of Neuron, Watabe-Uchida et al. link
a novel Rac-mediated pathway that regulates microtu-
bule dynamics to axon formation.
Polarization of most vertebrate neurons begins with the
specification of one neurite as the axon while other neu-
rites subsequently develop into dendrites. Although the
knockdown of DOCK7 expression blocks the develop-
ment of polarity, preventing the formation of an axon.
The investigators determine that regulation of Rac activ-
ity by DOCK7 seems to be important in its ability to pro-
mote axon formation.
It is interesting to note that other Rac-specific GEFs,
Tiam1 and STEF, have also been implicated in axon for-
mation. The implication suggests that the spatial and
temporal activity of Rac is important in axon specifica-
tion (Kunda et al., 2001; Nishimura et al., 2005). If neu-
rons have Tiam1 and STEF, why do they need DOCK7?
Perhaps different extracellular stimuli determine the
type of GEFs that activate Rac. Alternatively, these dif-
ferent GEFs may affect different downstream effector
molecules that Rac binds to and activates. It will be
